Jacek Mackiewicz
Overview
Explore the profile of Jacek Mackiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob J, Mohr P, et al.
Future Oncol
. 2024 Feb;
20(15):959-968.
PMID: 38390818
What Is This Summary About?: In this article, we summarize results from the ongoing phase 3 CheckMate 76K clinical study published online in in October 2023. The study goal was...
12.
Szostak N, Handschuh L, Samelak-Czajka A, Tomela K, Pietrzak B, Schmidt M, et al.
Cancer Immunol Res
. 2024 Feb;
12(4):427-439.
PMID: 38315788
Recent research indicates that gut microbiota may be vital in the advancement of melanoma. In this study, we found that melanoma patients exhibited a distinct gut mycobiota structure compared with...
13.
Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob J, Mohr P, et al.
Nat Med
. 2024 Jan;
30(3):906.
PMID: 38177857
No abstract available.
14.
Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob J, Mohr P, et al.
Nat Med
. 2023 Nov;
30(2):607.
PMID: 37923838
No abstract available.
15.
Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob J, Mohr P, et al.
Nat Med
. 2023 Oct;
29(11):2835-2843.
PMID: 37845511
Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected...
16.
Placzke J, Rosinska M, Sobczuk P, Zietek M, Kempa-Kaminska N, Cybulska-Stopa B, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686659
Background: The landscape of melanoma management changed as randomized trials have launched adjuvant treatment. Materials And Methods: An analysis of data on 248 consecutive melanoma stage III and IV patients...
17.
Galus L, Michalak M, Lorenz M, Stoinska-Swiniarek R, Tusien Malecka D, Galus A, et al.
Cancer
. 2023 Apr;
129(13):2047-2055.
PMID: 37089083
Background: Vitamin D3 is a prohormone with pleiotropic effects, including modulating the functions of the immune system and may affect the effectiveness of anti-PD-1 treatment in patients with cancer. According...
18.
Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus L, Ziolkowska B, et al.
Melanoma Res
. 2023 Apr;
33(3):208-217.
PMID: 37015054
Pembrolizumab and nivolumab (anty-PD-1 antibody) are commonly used for the treatment of melanoma patients. However, their efficacy and safety have never been directly compared, leaving little guidance for clinicians to...
19.
Kaminska P, Buszka K, Galus L, Jankowski M, Nowicki M, Mackiewicz J, et al.
Cells
. 2023 Mar;
12(6).
PMID: 36980196
Despite the rising public awareness of the risk factors and the possible prevention of melanoma development, it remains challenging in terms of diagnosis and treatment. To improve the clinical situation...
20.
Piejko K, Cybulska-Stopa B, Zietek M, Dziura R, Galus L, Kempa-Kaminska N, et al.
Target Oncol
. 2023 Mar;
18(2):235-245.
PMID: 36906728
Background: Combined treatment with BRAFi and/or MEK inhibitors (MEKi) improves outcomes in advanced melanoma patients in comparison with monotherapy. Objective: We aim to report real-world treatment efficacy and safety of...